Patent application number | Description | Published |
20080293106 | Method For the Mass Production of Immunoglobulin Fc Region Deleted Initial Methionine Residues - Disclosed is a method for the mass production of a monomeric or dimeric immunoglobulin Fc region, free of initial methionine residues, using a recombinant expression vector comprising a nucleotide sequence coding for a recombinant immunoglobulin Fc region comprising an immunoglobulin Fc region linked at the N-terminus thereof to an immunoglobulin Fc region via a peptide bond. | 11-27-2008 |
20090053246 | IMMUNOGLOBULIN FC FRAGMENT MODIFIED BY NON-PEPTIDE POLYMER AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are an Fc fragment modified by a non-peptide polymer, a pharmaceutical composition comprising the Fc fragment modified by the non-peptide polymer as a carrier, a complex of the Fc fragment and a drug via a linker and a pharmaceutical composition comprising such a complex. The Fc fragment modified by a non-peptide peptide according to the present invention lacks immunogenicity and effector functions. Due to these properties, the Fc fragment maintains the in vivo activity of a drug conjugated thereto in high levels, remarkably increases the serum half-life of the drug, and remarkably reduces the risk of inducing immune responses. | 02-26-2009 |
20090104660 | Expression vector for secreting antibody fragment using e. coli signal sequence and method for mass-producing antibody fragment - A recombinant expression vector capable of expressing and secreting an antibody fragment fused with | 04-23-2009 |
20090238838 | INSULINOTROPIC PEPTIDE CONJUGATE USING AN IMMUNOGLOBULIN FC - The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs. | 09-24-2009 |
20100105869 | Physiologically Active Polypeptide Conjugate Having Prolonged In Vivo Half-Life - A protein conjugate having a prolonged in vivo half-life of a physiological activity, comprising i) a physiologically active polypeptide, ii) a non-peptidic polymer, and iii) an immunoglobulin, is useful for the development of a polypeptide drug due to the enhanced in vivo stability and prolonged half-life in blood, while reducing the possibility of inducing an immune response. | 04-29-2010 |
20100105877 | AN INSULINOTROPIC COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT - The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs. | 04-29-2010 |
20100120089 | A NOVEL VECTOR AND EXPRESSION CELL LINE FOR MASS PRODUCTION OF RECOMBINANT PROTEIN AND A PROCESS OF PRODUCING RECOMBINANT PROTEIN USING SAME - Disclosed herein is an inducible high-expression cassette comprising a dihydrofolate reductase (DHFR) promoter from which GC-rich repeat sequences are partially or entirely removed, the cassette capable of more effectively improving a gene amplification system. Also disclosed are an expression vector comprising the inducible expression cassette and optionally a gene encoding a recombinant protein of interest, an animal cell line transformed with the expression vector, and a method of mass producing and purifying a recombinant protein by culturing the transformant. The present invention enables the shortening of the time required to establish a cell line producing a recombinant protein of interest at high levels using a low concentration of a DHFR inhibitor, thereby allowing more effective production of the recombinant protein. | 05-13-2010 |
20100204451 | INSULINOTROPIC PEPTIDE DERIVATIVE WHEREIN ITS N-TERMINAL AMINO ACID IS MODIFIED - The present invention relates to an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to a pharmaceutical composition comprising the same. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases. | 08-12-2010 |
20100255014 | Protein Complex Using An Immunoglobulin Fragment and Method For The Preparation Thereof - Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs. | 10-07-2010 |
20100261248 | Pharmaceutical Composition Comprising An Immunoglobulin FC Region as a Carrier - Disclosed is a novel use of an immunoglobulin Fc fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs. | 10-14-2010 |
20100330108 | PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASE COMPRISING INSULINOTROPIC PEPTIDE CONJUGATE - The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases. | 12-30-2010 |
20110071262 | METHOD FOR PREPARING HIGH-PURITY POLYETHYLENEGLYCOL ALDEHYDE DERIVATIVES - A method for preparing high-purity polyethyleneglycol-alkylenealdehydes and derivatives thereof is provided. | 03-24-2011 |
20110200623 | POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL POLYMER HAVING THREE FUNCTIONAL ENDS - Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified. | 08-18-2011 |
20110245472 | METHOD FOR THE MASS PRODUCTION OF IMMUNOGLOBULIN CONSTANT REGION - Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an | 10-06-2011 |
20120003712 | METHOD FOR PREPARING A SITE-SPECIFIC PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE - The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life. | 01-05-2012 |
20120294829 | LIQUID FORMULATIONS FOR LONG-ACTING G-CSF CONJUGATE - Disclosed is a liquid formulation which allows long-acting G-CSF conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting G-CSF conjugates. | 11-22-2012 |
20120296069 | LIQUID FORMULATIONS FOR LONG-ACTING ERYTHROPOIETIN CONJUGATE - Disclosed is a liquid formulation which allows long-acting EPO conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting EPO conjugates. | 11-22-2012 |
20130022626 | LONG-ACTING HUMAN FOLLICLE-STIMULATING HORMONE FORMULATION USING IMMUNOGLOBULIN FRAGMENT - The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof. | 01-24-2013 |
20130028867 | LONG-ACTING INTERFERON BETA FORMULATION USING IMMUNOGLOBULIN FRAGMENT - The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious. | 01-31-2013 |
20130028918 | INSULIN CONJUGATE USING AN IMMUNOGLOBULIN FRAGMENT - The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment. | 01-31-2013 |
20130095090 | FACTOR VIIA COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT - Disclosed are a blood coagulation factor complex in which FacVIIa, a non-peptidyl polymer and an immunoglobulin Fc region are bonded by covalent bonds, and the uses thereof. The FacVIIa complex guarantees the in vivo activity of FacVIIa and significantly enhances the serum half life of FacVIIa, so that it is useful for developing long-acting FacVIIa formulations which can improve the compliance of role behavior of patients whose blood does not coagulate. | 04-18-2013 |
20130115231 | LIQUID FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE - Disclosed is a liquid formulation of long-acting human growth hormone (hGH) conjugate, free of albumin, which can guarantee the stability of the long-acting hGH conjugate when stored over a long period of time, wherein the long-acting human growth hormone conjugate includes a human growth hormone linked to an immunoglobulin Fc region, and has a prolonged in vivo stability compared to the native form. The liquid formulation of hGH conjugate including a pH 5.0˜6.0 buffer, a sugar alcohol, a salt and a non-ionic surfactant is free of human serum albumin and other hazardous factors which are potentially contaminated with viruses, and can provide excellent storage stability customized for a long-acting hGH conjugate composed of an hGH polypeptide and an immunoglobulin Fc region which has higher molecular weight and in vivo durability, compared to the native. | 05-09-2013 |
20130122023 | NOVEL LONG-ACTING GLUCAGON CONJUGATE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR THE PREVENTION AND TREATMENT OF OBESITY - Disclosed is a novel long-acting glucagon conjugate in which glucagon or its derivative is covalently linked to a polymer carrier via a non-peptide linker, and a pharmaceutical composition comprising the same as an effective ingredient useful for the prevention and treatment of obesity. Since the long-acting glucagon conjugate of the present invention shows improved in vivo durability and stability, when used in combination with an anti-obesity drug, it is possible to induce synergistic effects on the loss of body weight and decrease in food intake without causing any side-effects such as fluctuation in blood glucose level. Accordingly, the long-acting peptide conjugate of the present invention is very effective for the prevention and treatment of obesity. | 05-16-2013 |
20130273634 | METHOD FOR MASS PRODUCTION OF FACTOR VII/VIIA - A method for the mass production of human coagulation factor VII. The method includes a) providing an expression vector carrying i) a dihydrofolate reductase promoter devoid of one or more CCGCC repeat sequences from the GC-rich region thereof and a dihydrofolate reductase (DHFR) gene operably linked thereto and ii) a cytomegalovirus (CMV) promoter and a human coagulation factor VII gene operably linked thereto; b) obtaining a transformed a host cell line containing the expression vector; and c) culturing the transfected host cell in the presence of a dihydrofolate reductase inhibitor to select cells which express human coagulation factor VII with high efficiency; and d) adding sodium butyrate to the selected host cells. | 10-17-2013 |
20130287734 | LIQUID FORMULATIONS OF LONG ACTING INTERFERON ALPHA CONJUGATE - Disclosed is a liquid formulation in which a long-acting INFα conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INFα conjugates. | 10-31-2013 |
20130288333 | PROTEIN COMPLEX USING AN IMMUNOGLOBULIN FRAGMENT AND METHOD FOR THE PREPARATION THEREOF - Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs. | 10-31-2013 |
20140107023 | NON-PEPTIDYL POLYMER-INSULIN MULTIMER AND METHOD FOR PRODUCING THE SAME - The present invention relates to a non-peptidyl polymer-insulin multimer comprising two or more of a non-peptidyl polymer-insulin conjugate prepared by linking a non-peptidyl polymer and insulin via a covalent bond, in which the conjugates are complexed with cobalt ion to form a multimer, a method and kit for the preparation of the multimer, a pharmaceutical composition for the prevention or treatment of diabetes comprising the multimer as an active ingredient, and a method for preventing or treating diabetes by administering the composition to a subject. | 04-17-2014 |
20140120120 | COMPOSITION FOR TREATING DIABETES COMPRISING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE - The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability. | 05-01-2014 |
20140128318 | NOVEL OXYNTOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY COMPRISING THE SAME - The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy. | 05-08-2014 |
20140212440 | CONJUGATE COMPRISING OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND USE THEREOF - The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy. | 07-31-2014 |
20140219961 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE - A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient. | 08-07-2014 |
20140271607 | BLOOD COAGULATION FACTOR VII AND VIIA DERIVATIVES, CONJUGATES AND COMPLEXES COMPRISING THE SAME, AND USE THEREOF - A blood coagulation factor VII derivative, a blood coagulation factor VIIa derivative, FacVII and FacVIIa conjugates are prepared by linking a polymer capable of extending the blood half-life to the derivative. FacVII and VIIa complexes each prepared by linking a carrier to the conjugate, genes encoding the FacVII and FacVIIa derivatives, expression vectors comprising the genes, transformants introduced with the expression vectors, a method for preparing the FacVII and FacVIIa derivatives using the transformants, a method for preparing the FacVIIa conjugate and complex, a FacVIIa complex prepared by the method, a pharmaceutical composition for the prevention or treatment of hemophilia comprising the derivative, conjugate, or complex as an active ingredient, and a pharmaceutical composition for blood coagulation comprising the derivative, conjugate, or complex as an active ingredient are described. | 09-18-2014 |
20140296475 | METHOD FOR PREPARING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX - A method for preparing a conjugate of a physiologically active polypeptide and a non-peptide polymer by linking physiologically active polypeptide with non-peptide polymer through a covalent bond using an organic solvent is provided. A method for preparing a physiologically active polypeptide complex by linking the conjugate with a carrier is provided. The complex shows improved in vivo duration and stability of the physiologically active polypeptide. The method can prepare the conjugate at a lower production cost, and the resulting conjugate shows an extension of in vivo activity at a relatively high level and significantly increase in the blood half-life. | 10-02-2014 |
20140357843 | IMMUNOGLOBULIN FC VARIANTS - The present invention relates to immunoglobulin Fc variants having an increased binding affinity for FcRn, which is characterized by including one or more amino acid modifications selected from the group consisting of 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K and 434S (this numbering is according to the EU index) in the constant region of a native immunoglobulin Fc fragment. Owing to the high binding affinity for FcRn, the immunoglobulin Fc variants according to the present invention show more prolonged in vivo half-life, and thus can be used for the preparation of a long-acting formulation of protein drugs. | 12-04-2014 |
20140377290 | SITE-SPECIFIC GLP-2 CONJUGATE USING AN IMMUNOGLOBULIN FRAGMENT - The present invention relates to a glucagon-like peptide-2 (GLP-2) conjugate comprising native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosia by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability. | 12-25-2014 |
20150025228 | IGG FC FRAGMENT FOR A DRUG CARRIER AND METHOD FOR THE PREPARATION THEREOF - Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug. | 01-22-2015 |
20150050692 | METHOD OF CULTURING E. COLI CELLS FOR HIGH DENSITY - Disclosed is a method of culturing | 02-19-2015 |
20150056223 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin Fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease. Ultimately, it can be desirably employed for the prevention and treatment of non-alcoholic fatty liver disease. | 02-26-2015 |